Singapore, July 8, 2010: Novavax, a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide announced the appointment of Dr Gregory Glenn, as the company's Chief Scientific Officer. He will report to Dr Rahul Singhvi, President and Chief Executive Officer of Novavax.

Previously, Dr Glenn was Chief Scientific Officer and founder of IOMAI Corporation (now Intercell), an associate in international health at Johns Hopkins University's School of Public Health and a clinical and basic research scientist at Walter Reed Army Institute of Research.

Dr Rahul Singhvi said, "Dr Greg Glenn is a recognized innovator and authority on vaccines, vaccine delivery and adjuvants. He brings to Novavax considerable experience in the discovery, development and clinical evaluation of a wide variety of vaccines to prevent diseases such as pandemic influenza, tetanus, malaria, HIV and cancer. As a co-founder of IOMAI, Greg also has an appreciation for the challenge of translating promising early-stage research into commercially viable, late-stage product candidates."

Dr Glenn stated, "The use of virus-like particles to mimic live viruses is a very promising approach to preventing the spread of infectious diseases. I look forward to supporting the development and application of this very promising approach to disease prevention."

Dr Glenn is a pioneer in vaccine delivery and adjuvants, and has brought several products from concept into clinical development including the travelers' diarrhea vaccine patch, and an adjuvant patch for a pandemic influenza vaccine, developed under US government contracts. He provided the scientific and technical leadership that led to the acquisition of IOMAI by Intercell in 2008. He has co-authored more than 150 research publications, scientific abstracts and presentations, and successful grant applications, and holds multiple US, European and other international patents.